For Quick Alerts
For Daily Alerts

Aurobindo Pharma gets tentative nod for tablets to treat HIV-1

By Religare

Manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, Aurobindo Pharma Ltd. has received the tentative approval from the US FDA to manufacture and market Efavirenz+Lamivudine+Tenofovir Disoproxil Fumarate tablets in the strengths of 600mg/300mg/300mg.

The New Drug Application (NDA) 22-343 provides for the use of these tablets alone or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults and adolescents aged over 16 years and weighting at least 40 kg, the company said in a filing to the Bombay Stock Exchange.


This NDA was reviewed under the President's Emergency Plan for AIDS Relief. The estimated ARV Access Market for the product is USD 120 million last year and expected to record strong growth in the coming year, the filing added.

Read more about: aurobindo pharma
Story first published: Friday, June 28, 2013, 22:57 [IST]
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more